Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Orphan Drug Boom: Gold Rush Or Flash In The Pan?

Related Content

Pfizer <em>Vyndaqel</em> Advisory Committee Pits Orphan Flexibility Vs. Data Shortcomings

May 23 2012

PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements

Sep 17 2012

Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations

Sep 26 2011

Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects

Dec 19 2011

Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Feb 01 2010

Novartis's Research Experiment

May 01 2006

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

Aug 29 2011

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now

Mar 01 2011

Related Companies

Sanofi Genzyme

Takeda Pharmaceutical Co. Ltd.

BioMarin Pharmaceutical Inc.

Actelion Pharmaceuticals Ltd.

Sanofi

Pfizer Inc.

GSK plc

Alexion Pharmaceuticals Inc.

Genetix Biotherapeutics

Ultragenyx Pharmaceutical Inc.

Synageva BioPharma Corp.

Sarepta Therapeutics, Inc.

Travere Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Novartis AG

Novartis AG

Merck & Co., Inc.

Eli Lilly and Company

Protalix BioTherapeutics, Inc.

Orphatec Pharmaceuticals GmbH

Takeda Pharmaceutical Co. Ltd.

Amicus Therapeutics, Inc.

Raptor Pharmaceutical Corp.

Viatris Inc.

NPS Pharmaceuticals, Inc.

InterMune, Inc.

uniQure N.V.

Additional Topics

BioPharmaceutical

More from In Vivo Archive

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window